CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

If You Invested $10,000 in CRISPR Therapeutics in 2019, This Is How Much You Would Have Today ↗

February 19, 2024

It would have been a great move.

Looking for high-growth opportunities? Here are three Cathie Wood stocks for long-term investors to consider now.

3 Stocks That Cathie Wood Is Loving Now: February 2024 ↗

February 16, 2024

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have...

What's Going On With Crispr Therapeutics Stock? ↗

February 15, 2024

Via Benzinga

Check Out What Whales Are Doing With CRSP ↗

February 14, 2024

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today ↗

February 09, 2024

Via Benzinga

Got $100? 2 Top Cathie Wood Stocks to Buy and Hold. ↗

February 04, 2024

These stocks are steals right now.

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday ↗

February 15, 2024

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

Via Benzinga

Topics Stocks

Gene therapy: Why does it cost millions for a single treatment?

February 15, 2024

Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Topics Artificial Intelligence

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ ↗

February 13, 2024

Via Investor's Business Daily

3 Gene Editing Stocks With Unprecedented Surge Potential ↗

February 13, 2024

While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.

The famous investor owns some huge winners -- and big losers, too.

Cathie Wood Has 37% of Her Ark Invest Portfolio Invested in These 7 Stocks ↗

February 12, 2024

Get the latest investment advice for healthcare stocks in 2024. Discover top picks and growth opportunities for the healthcare sector.

3 Groundbreaking Healthcare Stocks to Buy for Robust Gains ↗

February 11, 2024

These strong buy healthcare stocks are among analysts' favorite picks, and their strong market position tells us why.

3 Strong Buy Healthcare Stocks to Add to Your February Must-Watch List ↗

February 09, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

Both companies are proven innovators.

2 Healthcare Stocks to Buy Hand Over Fist in February ↗

February 08, 2024

They aren't all long shots, but they're all innovative.

Cathie Wood Just Bought These 3 Biotech Stocks. Should You? ↗

February 07, 2024

These two Cathie Wood holdings are great long-term buys.

2 Cathie Wood Stocks I Plan on Buying for My Kids' Portfolios ↗

February 05, 2024

Discover how emerging tech is shaping healthcare stocks in 2024. See which companies are outperforming and what it means for your portfolio.

Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements ↗

February 01, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is taking a "hard pass" on Surgery Partners, Inc. (NASDAQ: SGRY). "That industry has been up and down and up and down," he added.

Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock ↗

January 31, 2024

Via Benzinga

History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. ↗

January 30, 2024

Bull markets generally favor growth stocks, so now is a great time to buy quality growth players.

CRISPR Therapeutics is a specialist in the hot technology of gene editing.

Topics Stocks

Is CRISPR Therapeutics a Buy in the New Bull Market? ↗

January 30, 2024

Wood added to her existing positions in these three exciting companies.

Cathie Wood Goes Bargain Hunting: 3 Stocks She Bought Last Week ↗

January 28, 2024

These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions.

Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January ↗

January 25, 2024

Affirm, MongoDB, UIPath, Synopsys and Crispr's charts signal buy opportunities as these top-performing tech and biotech stocks consolidate below prior highs.

These 5 growth stocks are now in buy ranges

January 25, 2024

The company could maintain the momentum it gained last year.

Topics ETFs

Where Will CRISPR Therapeutics Be in 5 Years? ↗

January 24, 2024

Despite A bump in the road, the biotech's future looks sunny.

1 Setback and 1 Opportunity for CRISPR Therapeutics Stock ↗

January 23, 2024

Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

2 gene editing stocks to keep on your 2024 watchlist

January 23, 2024